AnaptysBio shares collapse after 'worst case scenario' for key drug

San Diego biotech AnaptysBio was worth about $700 million less Friday morning than when markets closed Thursday, after the failure of the company's most important drug candidate sparked a sharp sell-off on Wall Street.